Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 2
1978 1
1979 1
1980 2
1981 1
1982 5
1983 2
1984 1
1985 4
1986 7
1987 4
1988 5
1989 3
1990 6
1991 6
1992 11
1993 4
1994 13
1995 16
1996 18
1997 18
1998 28
1999 20
2000 24
2001 34
2002 32
2003 34
2004 41
2005 52
2006 56
2007 59
2008 66
2009 47
2010 44
2011 63
2012 57
2013 56
2014 61
2015 78
2016 85
2017 82
2018 87
2019 93
2020 132
2021 156
2022 145
2023 166
2024 60

Text availability

Article attribute

Article type

Publication date

Search Results

1,734 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Dermatitis, atopic, 7"
Page 1
Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis.
Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochwerg B, Di Giorgio S, Arents BWM, Burton T, Spuls PI, Schmitt J, Flohr C. Drucker AM, et al. JAMA Dermatol. 2022 May 1;158(5):523-532. doi: 10.1001/jamadermatol.2022.0455. JAMA Dermatol. 2022. PMID: 35293977 Free PMC article.
IMPORTANCE: Systemic treatments for atopic dermatitis are being evaluated primarily in placebo-controlled trials; network meta-analysis can provide relative efficacy and safety estimates for treatments that have not been compared head to head. OBJECTIVE: To compare …
IMPORTANCE: Systemic treatments for atopic dermatitis are being evaluated primarily in placebo-controlled trials; network meta …
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
Kabashima K, Matsumura T, Komazaki H, Kawashima M; Nemolizumab-JP01 Study Group. Kabashima K, et al. N Engl J Med. 2020 Jul 9;383(2):141-150. doi: 10.1056/NEJMoa1917006. N Engl J Med. 2020. PMID: 32640132 Clinical Trial.
BACKGROUND: Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic d …
BACKGROUND: Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved …
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, Forman SB, Venturanza ME, Sun K, Kuligowski ME, Simpson EL. Papp K, et al. J Am Acad Dermatol. 2021 Oct;85(4):863-872. doi: 10.1016/j.jaad.2021.04.085. Epub 2021 May 4. J Am Acad Dermatol. 2021. PMID: 33957195 Free article. Clinical Trial.
METHODS: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (NCT03745638) and Study 2 (NCT03745651) enrolled patients aged 12 years with AD for 2 years, an Investigator's Global Assessment score of 2/3, and 3%-20% affected body surface area. ...The p …
METHODS: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (NCT03745638) and Study 2 (NCT03745651) enrolled patients …
Dietary Elimination for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis.
Oykhman P, Dookie J, Al-Rammahy H, de Benedetto A, Asiniwasis RN, LeBovidge J, Wang J, Ong PY, Lio P, Gutierrez A, Capozza K, Martin SA, Frazier W, Wheeler K, Boguniewicz M, Spergel JM, Greenhawt M, Silverberg JI, Schneider L, Chu DK. Oykhman P, et al. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2657-2666.e8. doi: 10.1016/j.jaip.2022.06.044. Epub 2022 Jul 19. J Allergy Clin Immunol Pract. 2022. PMID: 35987995
BACKGROUND: The influence of diet on atopic dermatitis (AD) is complex, and the use of dietary elimination as a treatment has conflicting views. ...RESULTS: Ten RCT (n = 599; baseline median of study mean age, 1.5 years; median of study mean SCOring Atopic …
BACKGROUND: The influence of diet on atopic dermatitis (AD) is complex, and the use of dietary elimination as a treatment has …
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, Browning J, Soong W, Sun X, Chen Z, Kosloski MP, Kamal MA, Delevry D, Chuang CC, O'Malley JT, Bansal A. Blauvelt A, et al. Am J Clin Dermatol. 2022 May;23(3):365-383. doi: 10.1007/s40257-022-00683-2. Epub 2022 May 14. Am J Clin Dermatol. 2022. PMID: 35567671 Free PMC article. Clinical Trial.
Atopic dermatitis remains a problem for many adolescent patients, even if they use a number of different treatments. ...Almost half of the patients achieved skin that was clear or almost clear of atopic dermatitis during the study. But their atopic …
Atopic dermatitis remains a problem for many adolescent patients, even if they use a number of different treatments. ...Almost …
Vitamin D Status and Efficacy of Vitamin D Supplementation in Atopic Dermatitis: A Systematic Review and Meta-Analysis.
Kim MJ, Kim SN, Lee YW, Choe YB, Ahn KJ. Kim MJ, et al. Nutrients. 2016 Dec 3;8(12):789. doi: 10.3390/nu8120789. Nutrients. 2016. PMID: 27918470 Free PMC article. Review.
Recent literature has highlighted the possible role of vitamin D in atopic dermatitis (AD), and that vitamin D supplementation might help to treat AD. ...We searched the MEDLINE, EMBASE, and Cochrane databases up to May 2015. Observational studies and randomi …
Recent literature has highlighted the possible role of vitamin D in atopic dermatitis (AD), and that vitamin D supplementation …
Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial.
Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X, Schauer U, Qaqundah P, Poulin Y, Kristjansson S, von Berg A, Nieto A, Boguniewicz M, Paller AS, Dakovic R, Ring J, Luger T. Sigurgeirsson B, et al. Pediatrics. 2015 Apr;135(4):597-606. doi: 10.1542/peds.2014-1990. Epub 2015 Mar 23. Pediatrics. 2015. PMID: 25802354 Free article. Clinical Trial.
BACKGROUND AND OBJECTIVES: Atopic dermatitis (AD) primarily affects infants and young children. ...Treatment success was defined as an Investigator's Global Assessment score of 0 (clear) or 1 (almost clear). RESULTS: Both PIM and TCSs had a rapid onset of act …
BACKGROUND AND OBJECTIVES: Atopic dermatitis (AD) primarily affects infants and young children. ...Treatment success was defin …
The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials.
Yoon S, Kim K, Shin K, Kim HS, Kim B, Kim MB, Ko HC, Kim YH. Yoon S, et al. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):52-61. doi: 10.1111/jdv.19426. Epub 2023 Aug 25. J Eur Acad Dermatol Venereol. 2024. PMID: 37597261 Review.
Janus kinase (JAK) inhibitors have been recently approved by the FDA and are widely used in the treatment of patients with atopic dermatitis. However, a comprehensive safety profile of JAK inhibitors in patients with atopic dermatitis has not been anal …
Janus kinase (JAK) inhibitors have been recently approved by the FDA and are widely used in the treatment of patients with atopic …
Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.
Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, Moate R, van der Merwe R. Wollenberg A, et al. J Allergy Clin Immunol. 2019 Jan;143(1):135-141. doi: 10.1016/j.jaci.2018.05.029. Epub 2018 Jun 12. J Allergy Clin Immunol. 2019. PMID: 29906525 Free article. Clinical Trial.
BACKGROUND: IL-13 has an important role in atopic dermatitis (AD) pathogenesis. Tralokinumab is a fully human mAb that potently and specifically neutralizes IL-13. ...RESULTS: At week 12, 300 mg of tralokinumab significantly improved change from baseline in Eczema A …
BACKGROUND: IL-13 has an important role in atopic dermatitis (AD) pathogenesis. Tralokinumab is a fully human mAb that potentl …
Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study.
Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Simpson EL, Ong PY, Chiesa Fuxench ZC. Silverberg JI, et al. Ann Allergy Asthma Immunol. 2018 Sep;121(3):340-347. doi: 10.1016/j.anai.2018.07.006. Epub 2018 Jul 16. Ann Allergy Asthma Immunol. 2018. PMID: 30025911 Free article.
BACKGROUND: The patient burden and quality of life (QOL) impact of atopic dermatitis (AD) in the United States population is not well established. ...Concurrently, severe PO-SCORAD, POEM, or PO-SCORAD-itch was associated with very low mean SF-12 mental health (34. …
BACKGROUND: The patient burden and quality of life (QOL) impact of atopic dermatitis (AD) in the United States population is n …
1,734 results